REWARD

Performance-based Innovation Rewards

Coordinatore	UNIVERSITY OF CENTRAL LANCASHIRE    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	1˙922˙338 €
EC contributo	1˙922˙338 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-ADG
Funding Scheme	ERC-AG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-02-01   -   2019-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	RESEARCH AND INFORMATION SYSTEM FOR DEVELOPING COUNTRIES  Organization address address: "LODHI ROAD, INDIA HABITAT CENTRE, CORE 4B 4th FLOOR" city: NEW DELHI postcode: 110 003 contact info Titolo: Dr. Nome: Sachin Cognome: Chaturvedi Email: send email Telefono: 911125000000	IN (NEW DELHI)	beneficiary	136˙927.20
2	UNIVERSITY OF CENTRAL LANCASHIRE  Organization address address: - city: PRESTON postcode: PR1 2HE contact info Titolo: Dr. Nome: Alexis Cognome: Holden Email: send email Telefono: +44 1772892562	UK (PRESTON)	hostInstitution	1˙785˙411.20
3	UNIVERSITY OF CENTRAL LANCASHIRE  Organization address address: - city: PRESTON postcode: PR1 2HE contact info Titolo: Prof. Nome: Thomas Winfried Menko Cognome: Pogge Email: send email Telefono: 49228282749 Fax: 441773000000	UK (PRESTON)	hostInstitution	1˙785˙411.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'REWARD will open up new horizons in complementing the international intellectual property rights (IPR) system. The project's ambitious output is an ethically and legally sound performance-based reward mechanism for pharmaceutical innovation, which complements the existing patent regime, yet mitigates its considerable disadvantages for the global poor.

The current IPR system impedes access to life-saving medicines for the poor in two main ways. First, high prices for pharmaceutical innovations are required to recoup research and development costs through time-limited patent protection. Whilst high price levels maintain incentives for pharmaceutical innovation, they price new medicines beyond the range of the poor creating an accessibility problem. At the same time, diseases that burden the poor are often not worthy of investment for pharmaceutical innovators, creating an availability problem ('neglected diseases').

Many international research groups are working on IPR reform plans based on performance-based rewards for pharmaceutical innovation. However, their efforts are disparate and lacking a guiding vision. REWARD will use world-class ethics research as the steering force to determine which performance-based reward mechanism for pharmaceutical innovation is the most promising. In an interdisciplinary collaboration of ethicists, lawyers, economists, and statisticians, with experts in medicine, science and technology policy and gender studies the selected mechanism will be tested in a developed and a developing country.'